Eyenovia, Inc. (EYEN): Price and Financial Metrics

Eyenovia, Inc. (EYEN)

Today's Latest Price: $3.63 USD

0.18 (5.22%)

Updated Nov 27 1:00pm

Add EYEN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

EYEN Stock Price Chart Interactive Chart >

Price chart for EYEN

EYEN Price/Volume Stats

Current price $3.63 52-week high $6.92
Prev. close $3.45 52-week low $1.11
Day low $3.43 Volume 126,282
Day high $3.71 Avg. volume 402,733
50-day MA $3.38 Dividend yield N/A
200-day MA $3.30 Market Cap 90.33M

Eyenovia, Inc. (EYEN) Company Bio

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.

EYEN Latest News Stream

Event/Time News Detail
Loading, please wait...

EYEN Latest Social Stream

Loading social stream, please wait...

View Full EYEN Social Stream

Latest EYEN News From Around the Web

Below are the latest news stories about Eyenovia Inc that investors may wish to consider to help them evaluate EYEN as an investment opportunity.

Eyenovia under pressure on planned equity offering

Eyenovia (EYEN) initiates a public offering of common stock. Price, volume and terms have yet to be announced.Shares down 16% after hours....

Seeking Alpha | August 18, 2020

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript

Eyenovia, Inc. (EYEN) Q2 2020 Earnings Conference Call August 12, 2020 04:30 PM ET Company Participants Alexander Lobo - The Ruth Group Sean Ianchulev - Chief Executive Officer & Chief Medical Officer Michael Rowe - Vice President, Commercial John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan -...

SA Transcripts on Seeking Alpha | August 13, 2020

The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hittin...

Benzinga | August 12, 2020

Eyenovia Reports Second Quarter 2020 Financial Results

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of…

GlobeNewswire | August 12, 2020

Thinking about buying stock in Delta Air Lines, Eyenovia Inc, Sunesis Pharmaceuticals, Inovio Pharmaceuticals, or Moderna Inc?

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, EYEN, SNSS, INO, and MRNA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | August 11, 2020

Read More 'EYEN' Stories Here

EYEN Price Returns

1-mo 8.04%
3-mo 5.22%
6-mo 25.61%
1-year -11.46%
3-year N/A
5-year N/A
YTD -18.97%
2019 57.19%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.2046 seconds.